Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Jiangsu Hengrui Pharmaceuticals Co., Ltd.
江蘇恒瑞醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1276)

PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION

This announcement is made pursuant to Rule 13.51(1) of the Rules Governing the Listing of Securities (the "**Listing Rules**") on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**").

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (the "**Company**") convened a meeting of the board of directors (the "**Board**") of the Company (the "**Directors**") on December 10, 2025, at which, amongst others, the resolution in relation to the proposed amendments to the articles of association of the Company (the "**Articles of Association**") was considered and approved.

BACKGROUND OF THE PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION

Proposed Expansion of Business Scope

Based on the Company's practical operational and development needs, it is proposed that the Company's business scope be expanded to include "the research, development, production, and sales of pharmaceutical packaging materials and pharmaceutical packaging products". Corresponding provisions of the Articles of Association will be amended accordingly.

Proposed Abolishment of the Supervisory Committee

In order to comply with the requirements of the Company Law of the People's Republic of China (the "**Company Law**"), the Transitional Period Arrangements for the Implementation of the Rules of the Ancillary System under the New 'Company Law' (《關於新<公司法>配套制度規則實施相關過渡期安排》), the Guidelines on the Articles of Association of Listed Companies (《上市公司章程指引》), the listing rules of the Shanghai Stock Exchange (《上海證券交易所股票上市規則》), the Listing Rules and other relevant laws, regulations, rules and other normative documents, and in light of the actual circumstances of the Company, the Company proposes to abolish the supervisory committee of the Company (the "**Supervisory Committee**"). The powers and functions originally exercised by the Supervisory Committee under the Articles of Association will be assumed by the audit committee of the Board. Consequently, the rules of procedure for the Supervisory Committee and provisions in the Company's governing policies pertaining to the Supervisory Committee and the supervisors of the Company will be repealed.

PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION

To further enhance the Company's standardized operational standards, and in light of the proposed expansion of the Company's business scope and the provisions of the aforesaid laws, regulations, rules and other normative documents, the Company proposes to amend its Articles of Association. The proposed amendments include, amongst others, expanding the business scope of the Company, abolishing the Supervisory Committee and other housekeeping changes, including updates to the registered capital of the Company.

The proposed amendments to the Articles of Association will become effective upon (i) consideration and approval by the shareholders of the Company (the "**Shareholders**") at the extraordinary Shareholders' meeting, and (ii) final approval by and registration with the market regulatory authorities of the People's Republic of China.

EXTRAORDINARY SHAREHOLDERS' MEETING

The Company will propose a special resolution at an extraordinary Shareholders' meeting for the purpose of, *inter alia*, considering and approving the proposed amendments to the Articles of Association. A circular containing (among other things) the details of the proposed amendments to the Articles of Association will be published on the websites of the Stock Exchange (www.hkexnews.hk) and the Company (www.hengrui.com) in due course.

By order of the Board
Jiangsu Hengrui Pharmaceuticals Co., Ltd
江蘇恒瑞醫藥股份有限公司
Mr. Sun Piaoyang
Chairman

Shanghai, PRC
December 10, 2025

As at the date of this announcement, the Board comprises: (i) Mr. Sun Piaoyang, Mr. Dai Hongbin, Ms. Feng Ji, Mr. Zhang Lianshan, Mr. Jiang Frank Ningjun and Mr. Sun Jieping as executive Directors; (ii) Ms. Guo Congzhao as non-executive Director; and (iii) Mr. Dong Jiahong, Mr. Zeng Qingsheng, Mr. Sun Jinyun and Mr. Chow Kyan Mervyn as independent non-executive Directors.